Skip to content

Clinical trials

Observational Cardiomyopathy, Hypertrophic trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathy, Hypertrophic Phase: Observational Country / region: China Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20113
20151
20161
20174
20203
20211
20222
20235
20245
20253
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status12
Completed8
Recruiting6
Active, not recruiting3
Not yet recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Xijing Hospital7
China National Center for Cardiovascular Diseases4
Chinese Academy of Medical Sciences, Fuwai Hospital4
Beijing Institute of Heart, Lung and Blood Vessel Diseases2
Bristol-Myers Squibb2
Second Affiliated Hospital, Zhejiang University, School of Medicine2
Tongji Hospital2
Changrong Nie1
First Hospital of China Medical University1
Guangdong Provincial People's Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathy, Hypertrophic32
Cardiomyopathy, Dilated4
Arrhythmogenic Right Ventricular Dysplasia3
Hypertrophy, Left Ventricular3
Cardiomyopathy, Restrictive2
Fabry Disease2
Postoperative Complications2
Amyloid Neuropathies, Familial1
Arrhythmias, Cardiac1
Atrial Fibrillation1

Trials

Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.